Patents
More topics under "C07D - Heterocyclic compounds" (1,537,440)
C07D 201 - Preparation, separation, purification, or stabilisation of unsubstituted lactams (2,192)
C07D 203 - Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom (1,097)
C07D 205 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom (6,868)
C07D 207 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom (40,304)
C07D 209 - Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom (45,780)
C07D 211 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings (37,939)
C07D 213 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members (63,273)
C07D 215 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems (27,676)
C07D 217 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems (11,865)
C07D 219 - Heterocyclic compounds containing acridine or hydrogenated acridine ring systems (2,120)
C07D 221 - Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups (10,931)
C07D 223 - Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom (8,732)
C07D 225 - Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom (1,649)
C07D 227 - Heterocyclic compounds containing rings having one nitrogen atom as the only ring hetero atom, according to more than one of groups (473)
C07D 229 - Heterocyclic compounds containing rings of less than five members having two nitrogen atoms as the only ring hetero atoms (515)
C07D 231 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings (25,550)
C07D 233 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings (34,408)
C07D 235 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings (15,325)
C07D 237 - Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings (8,468)
C07D 239 - Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings (42,619)
C07D 241 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings (18,673)
C07D 243 - Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms (5,961)
C07D 245 - Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms (898)
C07D 247 - Heterocyclic compounds containing rings having two nitrogen atoms as the only ring hetero atoms, according to more than one of groups (239)
C07D 249 - Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms (17,749)
C07D 251 - Heterocyclic compounds containing 1,3,5-triazine rings (10,913)
C07D 253 - Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group (2,967)
C07D 255 - Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups (739)
C07D 257 - Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms (9,612)
C07D 259 - Heterocyclic compounds containing rings having more than four nitrogen atoms as the only ring hetero atoms (488)
C07D 261 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings (11,459)
C07D 263 - Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings (20,978)
C07D 265 - Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms (11,132)
C07D 267 - Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms (2,022)
C07D 269 - Heterocyclic compounds containing rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms according to more than one of groups (111)
C07D 271 - Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms (7,144)
C07D 273 - Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups (2,368)
C07D 275 - Heterocyclic compounds containing 1, 2-thiazole or hydrogenated 1,2-thiazole rings (4,972)
C07D 277 - Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings (33,621)
C07D 279 - Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms (5,149)
C07D 281 - Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms (1,924)
C07D 283 - Heterocyclic compounds containing rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms, according to more than one of groups (102)
C07D 285 - Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups (9,964)
C07D 291 - Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms (1,087)
C07D 293 - Heterocyclic compounds containing rings having nitrogen and selenium or nitrogen and tellurium, with or without oxygen or sulfur atoms, as the ring hetero atoms (553)
C07D 295 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms (34,005)
C07D 301 - Preparation of oxiranes (10,136)
C07D 303 - Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom (12,512)
C07D 305 - Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms (5,442)
C07D 307 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom (47,108)
C07D 309 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings (12,815)
C07D 311 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings (24,127)
C07D 313 - Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom (3,580)
C07D 315 - Heterocyclic compounds containing rings having one oxygen atom as the only ring hetero atom according to more than one of groups (1,360)
C07D 317 - Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms (18,224)
C07D 319 - Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms (10,283)
C07D 321 - Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups (2,079)
C07D 323 - Heterocyclic compounds containing more than two oxygen atoms as the only ring hetero atoms (1,581)
C07D 325 - Heterocyclic compounds containing rings having oxygen as the only ring hetero atom according to more than one of groups (168)
C07D 327 - Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms (2,428)
C07D 329 - Heterocyclic compounds containing rings having oxygen and selenium or oxygen and tellurium atoms as the only ring hetero atoms (47)
C07D 331 - Heterocyclic compounds containing rings of less than five members, having one sulfur atom as the only ring hetero atom (456)
C07D 333 - Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom (32,883)
C07D 335 - Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom (4,725)
C07D 337 - Heterocyclic compounds containing rings of more than six members having one sulfur atom as the only ring hetero atom (875)
C07D 339 - Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms (3,352)
C07D 341 - Heterocyclic compounds containing rings having three or more sulfur atoms as the only ring hetero atoms (281)
C07D 343 - Heterocyclic compounds containing rings having sulfur and selenium or sulfur and tellurium atoms as the only ring hetero atoms (52)
C07D 345 - Heterocyclic compounds containing rings having selenium or tellurium atoms as the only ring hetero atoms (419)
C07D 347 - Heterocyclic compounds containing rings having halogen atoms as ring hetero atoms (38)
C07D 401 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom (107,979)
C07D 403 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group (62,587)
C07D 405 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom (69,397)
C07D 407 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group (11,963)
C07D 409 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms (52,226)
C07D 411 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms (2,465)
C07D 413 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms (64,687)
C07D 415 - Heterocyclic compounds containing the thiamine skeleton (90)
C07D 417 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group (62,773)
C07D 419 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms (1,431)
C07D 421 - Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms (480)
C07D 451 - Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.02,4] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof (5,273)
C07D 453 - Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids (5,704)
C07D 455 - Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine (2,122)
C07D 457 - Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula: , e.g. lysergic acid (836)
C07D 459 - Heterocyclic compounds containing benz [g] indolo [2, 3-a] quinolizine ring systems, e.g. yohimbine; 16, 18-lactones thereof, e.g. reserpic acid lactone (97)
C07D 461 - Heterocyclic compounds containing indolo [3, 2, 1-d, e] pyrido [3, 2, 1-i, j] [1, 5]-naphthyridine ring systems, e.g. vincamine (286)
C07D 463 - Heterocyclic compounds containing 1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: , e.g. carbacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (613)
C07D 471 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups (64,559)
C07D 473 - Heterocyclic compounds containing purine ring systems (11,932)
C07D 475 - Heterocyclic compounds containing pteridine ring systems (2,718)
C07D 477 - Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula: , e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (2,484)
C07D 487 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups (57,272)
C07D 489 - Heterocyclic compounds containing 4ah-8, 9 c- iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: (2,334)
C07D 491 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or (29,726)
C07D 493 - Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system (17,376)
C07D 495 - Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms (21,336)
C07D 497 - Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms (1,069)
C07D 498 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms (21,960)
C07D 499 - Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula: , e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (3,448)
C07D 501 - Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: , e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (7,574)
C07D 503 - Heterocyclic compounds containing 4-oxa-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula: , e.g. oxapenicillins, clavulanic acid derivatives; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (648)
C07D 505 - Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: , e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (556)
C07D 507 - Heterocyclic compounds containing a condensed beta-lactam ring system, not provided for by groups , or; Such ring systems being further condensed (161)
C07D 513 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups , or (15,120)
C07D 515 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups , or (877)
C07D 517 - Heterocyclic compounds containing in the condensed system at least one hetero ring having selenium, tellurium, or halogen atoms as ring hetero atoms (452)
C07D 519 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or (11,041)
C07D 521 - Heterocyclic compounds containing unspecified hetero rings (16,203)
Patents for C07D - Heterocyclic compounds (10,420)
04/2004
04/28/2004EP0513200B2 Method and compositions for the synthesis of bch-189 and related compounds
04/28/2004CN1492852A N-phenpropylcyclopentyl-substituted glutaramide derivatives as NEP inhibitors for FSAD
04/27/2004US6727251 Inhibitors of glycogen synthase kinase-3 (gsk-3) and aurora-2, both serine/threonine protein kinases; for treating diseases such as cancer, diabetes and alzheimer's disease
04/22/2004WO2004033423A2 Anticancer compounds
04/22/2004WO2004033421A2 Improved production of bacterial strains
04/22/2004WO2002098857A8 New indole derivatives with 5-ht6 receptor affinity
04/22/2004US20040077703 Nodulisporic acid derivative spot-on formulations for combating parasites
04/22/2004US20040077642 Pyrimidine compounds
04/22/2004CA2501901A1 Anticancer compounds
04/21/2004EP1411049A1 Estrogen Agonists/Antagonists
04/21/2004EP1409487A1 Pteridinones as kinase inhibitors
04/21/2004EP1409477A1 Piperidine derivatives as nmda receptor antagonists
04/21/2004EP1409472A1 Method for the preparation of escitalopram
04/21/2004CN1146540C Novel compound with analgesic effect and use thereof
04/20/2004US6723726 Protein tyrosine kinase inhibitors
04/15/2004WO2004030457A1 Nodulisporic acid derivative spot-on formulations for combating parasites
04/15/2004CA2500822A1 Nodulisporic acid derivative spot-on formulations for combating parasites
04/14/2004EP1406873A2 Fluoropyrrolidines as dipeptidyl peptidase inhibitors
04/14/2004EP1406625A1 A PROCESS FOR PREPARING PAROXETINE HCl WHICH LIMITS FORMATION OF PINK COLORED COMPOUNDS
04/14/2004EP1115708B1 Aminoalkyl-3,4-dihydroquinoline derivates as no-synthase inhibitors
04/14/2004EP1028110B1 Novel dihydronaphthalene compounds and process for producing the same
04/14/2004CN1489592A 3,7-diazabicyclo[3,3,o] otanes and their use in treatment of cardiac arrhythmias
04/14/2004CN1489590A Compounds specific to adenosine A1, A2, and A3 receptor and uses thereof
04/14/2004CN1489588A Thiazolyl-oxazolyl-pyrrolyl-and imidazolyl-acid amide derivatives useful as inbibitors of PDE 4 isozymes
04/14/2004CN1489585A Process for producing substituted 2-(2-pyridylmethye)sulfinye-1H-benzinmidazoles
04/14/2004CN1145486C Pharmaceutical compositions containing eletriptan hemisulphate and coffeine
04/13/2004US6720336 4,4-biarylpiperidine derivatives
04/08/2004WO2004029034A1 Synthesis of thiophenecarboxylic acid esters for the production of ranelic acid salts
04/08/2004WO2004029025A2 Methods and compositions for the treatment of autoimmune disorders using clofarabine
04/08/2004WO2004012496A3 Method for producing an avocado unsaponifiable rich in furan lipids
04/08/2004US20040067945 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
04/08/2004US20040067940 Antiischemic agents; antiinflammatory agents; antiallergens; autoimmune disease
04/08/2004CA2500360A1 Methods and compositions for the treatment of autoimmune disorders using clofarabine
04/07/2004EP1405852A1 Diamine derivatives
04/07/2004EP1404667A1 Piperidine derivatives useful as modulators of chemokine receptor activity
04/07/2004EP1102733B1 Method for reacting an organic compound with a hydroperoxide
04/07/2004CN1487933A Pyrazole compounds useful as protein kinase inhibitors
04/07/2004CN1144805C Bridged bispidine compounds, its preparing method and intermediate and use for treatment of cardiac arrhythmias
04/07/2004CN1144789C Pyrrolidine and piperidine derivatives, producing process and application thereof
04/06/2004US6716981 Process for the preparation of N-(amino-4, 6-dihalo-pyrimidine) formamides
04/01/2004WO2004026820A2 Method for assaying compounds that decrease the activity of poly(adp-ribose)-polymerase (parp)
04/01/2004WO2003097597A3 Indole derivatives and the use thereof as cb2 receptor ligands
04/01/2004WO2003082874A3 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino[4,5-b]indole-1-acetamide derivatives, preparation and use thereof in medicaments
04/01/2004US20040063767 Reacting an alpha-substituted ketone with a cyclictetramine to form quaternaryammonium salt, reacting the salt with an acid to form alpha-amino ketone, reacting ketone with alpha-substitued acyl derivative in presence of a base
04/01/2004US20040063759 Administering to a mammal, for treatment or prevention of conditions that can be treated or prevented by antagonizing the CCR1 receptor in a mammal, a piperidinone compound
04/01/2004US20040063746 For treatment of HIV
04/01/2004CA2499383A1 Method for assaying compounds that decrease the activity of poly(adp-ribose)-polymerase (parp)
03/2004
03/31/2004EP1403265A1 Industrial process for the synthesis of 5-[bis(carboxymethyl)amino]-3-carboxymethyl-4-cyano-2-thiophene-carboxylic acid tetraesters and use for the synthesis of ranetic acid divalent salts and hydrates thereof
03/31/2004EP1401828A1 N-formyl hydroxylamine compounds as inhibitors of pdf
03/31/2004EP1401813A1 New indole derivatives with 5-ht6 receptor affinity
03/31/2004EP1401451A2 Quinazoline derivatives which promote the release of parathyroid hormone
03/31/2004EP1181294B1 Novel derivatives and analogues of galanthamin
03/31/2004CN1486312A Pyrazole compounds useful as protein kinase inhibitors
03/31/2004CN1486311A Pyrazole compounds useful as protein kinase inhibitors
03/31/2004CN1486310A Pyrazole compounds useful as protein kinase inhibitors
03/31/2004CN1486176A Pharmaceutical compositions comprising amlodipine maleate
03/31/2004CN1143853C Preparing method for anti-viral compounds
03/30/2004CA2314115C Process for the optical resolution of the racemic 6-(4-amino-phenyl)-5- methyl-pyridazin-3(2h)one
03/25/2004WO2004024734A1 Antidepressant indolealkyl derivatives of heterocycle-fused benzodioxan methylamines
03/25/2004WO2003104207A3 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
03/25/2004WO2003087050A3 Novel perindopril salt and pharmaceutical compositions containing same
03/25/2004US20040059134 Introducing in a reactor a5-amino-3-(carboxyalkyl)-4-cyano-2-thiophenecarboxylic acid, potassium carbonate and a quaternaryammonium salt as catalyst acetone solvent and methyl bromo acetate, heating and cooling
03/25/2004US20040059132 Reacting an indolin-2-one derivative with substituted benzyl halide to form substituted N-benzyl indolin-2-one derivatives have an affinity for oxytocin receptors
03/25/2004US20040058978 Novel substituted indolines with an inhibitory effect on various kinases and complexes of CDKs
03/25/2004US20040058935 Crystals; storage stability; psychological disorders
03/25/2004US20040058908 Mixture of bile acid transport inhibitor, cholesteryl ester transport protein inhibitor, fibric acid, nicotinic acid, microsomal triglyceride transfer protein inhibitor and sterols
03/25/2004CA2497214A1 Antidepressant indolealkyl derivatives of heterocycle-fused benzodioxan methylamines
03/24/2004EP1399445A2 Substituted pyrroloquinolines and pyridoquinolines as serotonin agonists and antagonists
03/24/2004CN1484640A Quinzolone derivatives as alpha IA/B adrenergic receptor antagonists
03/24/2004CN1142922C Intermediate used in preparing oxidiazine and its manufacturing method
03/24/2004CN1142904C One-step process synthetizing 2-oxazolidone derivative interediate and preparation process thereof
03/23/2004US6710209 Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents
03/23/2004US6710184 Crystalline solids of carvedilol and processes for their preparation
03/18/2004WO2004021989A2 Imidazolopyridines and methods of making and using the same
03/18/2004US20040054186 Autoimmune diseases; anticancer agents; antiproliferative agents; skin disorders
03/18/2004US20040053986 3,7-Diazabicyclo[3.3.0]octanes and their use in the treatment of cardiac arrhythmias
03/18/2004US20040053931 Kinase inhibitors; angiogenesis inhibitors, anticancer agents, antiinflammatory agents and chronic obstructive pulmonary disease inhibitors
03/18/2004CA2497968A1 Imidazolopyridines and methods of making and using the same
03/17/2004EP1397360A1 Azaindoles
03/17/2004EP1305318B1 Process for the preparation of 9-amino substituted 9,10-dihydropyrrolo [2,1-b] [1,3]benzothiazepines
03/17/2004EP1242406B1 Novel compounds
03/17/2004EP1192154B1 Bispidine compounds useful in the treatment of cardiac arrhythmias
03/17/2004EP1140936B1 Tricyclic inhibitors of poly(adp-ribose) polymerases
03/17/2004EP1140820B1 New amidino derivatives and their use as thrombin inhibitors
03/17/2004EP1137644B9 Benzofuran derivatives, their preparation and use
03/17/2004EP1135391B1 Novel triazolo(4,5-d)pyrimidine compounds
03/17/2004EP0891362B1 Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase
03/17/2004CN1142144C 4-phenyl pyridine derivatives
03/17/2004CN1142138C Preparation of thiol-carbamate and sulfocyanic ester compound
03/16/2004US6706896 Process for selective derivatization of taxanes
03/16/2004US6706878 Spiroazabicyclic heterocyclic compounds
03/16/2004US6706765 Aminoguanidines and alkoxyguanidines as protease inhibitors
03/11/2004WO2004020406A2 Variants of vibrio cholerae o1 biotype e1 tor with attributes of classical biotype
03/11/2004WO2004020404A2 Modified transferin-antibody fusion proteins
03/11/2004US20040049083 Arylpiperazines having activity at the serotonin 1A receptor
03/11/2004US20040048912 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
03/11/2004US20040048903 Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes
03/11/2004CA2495207A1 Modified transferin-antibody fusion proteins
03/10/2004CN1481387A Condensed purine derivatives as A1 adenosine receptor antagonists
03/10/2004CN1480451A Photoactive compound used as intermediate for preparing photoactive 2-imidazoline-5-ketone or 2-imdazoline-5-thio-ketone derivative
1 ... 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 ... 105